These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32923587)

  • 1. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy.
    Au KM; Park SI; Wang AZ
    Sci Adv; 2020 Jul; 6(27):eaba8564. PubMed ID: 32923587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
    Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.
    Ulitzka M; Harwardt J; Lipinski B; Tran H; Hock B; Kolmar H
    Molecules; 2024 Mar; 29(5):. PubMed ID: 38474651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer.
    Zhang H; Li Y; Kang H; Lan J; Hou L; Chen Z; Li F; Liu Y; Zhao J; Li N; Wan Y; Zhu Y; Zhao Z; Zhang H; Zhuang J; Huang X
    J Nanobiotechnology; 2024 Mar; 22(1):104. PubMed ID: 38468289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex Vivo Surface Decoration of Phenylboronic Acid onto Natural Killer Cells for Sialic Acid-Mediated Versatile Cancer Cell Targeting.
    Jangid AK; Kim S; Park HW; Kim HJ; Kim K
    Biomacromolecules; 2024 Jan; 25(1):222-237. PubMed ID: 38130077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo.
    Vallera DA; Ferrone S; Kodal B; Hinderlie P; Bendzick L; Ettestad B; Hallstrom C; Zorko NA; Rao A; Fujioka N; Ryan CJ; Geller MA; Miller JS; Felices M
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
    Upadhyaya P; Lahdenranta J; Hurov K; Battula S; Dods R; Haines E; Kleyman M; Kristensson J; Kublin J; Lani R; Ma J; Mudd G; Repash E; Van Rietschoten K; Stephen T; You F; Harrison H; Chen L; McDonnell K; Brandish P; Keen N
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-1BB (CD137) in anticancer chimeras.
    Melero I; Berraondo P
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 33147322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Author Correction: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
    Min Y; Roche KC; Tian S; Eblan MJ; McKinnon KP; Caster JM; Chai S; Herring LE; Zhang L; Zhang T; DeSimone JM; Tepper JE; Vincent BG; Serody JS; Wang AZ
    Nat Nanotechnol; 2021 Jun; 16(6):743-744. PubMed ID: 33580223
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring the NK cell platform for cancer immunotherapy.
    Myers JA; Miller JS
    Nat Rev Clin Oncol; 2021 Feb; 18(2):85-100. PubMed ID: 32934330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
    Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
    Front Immunol; 2021; 12():732135. PubMed ID: 34925314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.
    Capuano C; Pighi C; Battella S; De Federicis D; Galandrini R; Palmieri G
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.
    Huang L; Huang Z; Zhang Y; Lin C; Zhao Z; Li R; Saw PE; Xu X
    Theranostics; 2024; 14(14):5528-5550. PubMed ID: 39310113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity.
    Ye QN; Zhu L; Liang J; Zhao DK; Tian TY; Fan YN; Ye SY; Liu H; Huang XY; Cao ZT; Shen S; Wang J
    Nat Commun; 2024 Jul; 15(1):6211. PubMed ID: 39043643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury.
    Kandell RM; Wu JR; Kwon EJ
    Adv Mater; 2024 Aug; 36(31):e2301738. PubMed ID: 38780012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving Tumor Characteristics and Smart Nanodrugs for Tumor Immunotherapy.
    Sun W; Xie S; Liu SF; Hu X; Xing D
    Int J Nanomedicine; 2024; 19():3919-3942. PubMed ID: 38708176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering.
    Cui H; Zhang L; Shi Y
    Immunooncol Technol; 2024 Mar; 21():100695. PubMed ID: 38405432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.
    Liu J; Yang J; Pan Q; Wang X; Wang X; Chen H; Zheng X; Huang Q
    Eur J Med Res; 2024 Jan; 29(1):79. PubMed ID: 38281029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?
    Bjorgen JC; Dick JK; Cromarty R; Hart GT; Rhein J
    Front Immunol; 2023; 14():1267774. PubMed ID: 37928543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.